Snapshot: August Highlights
A selection of articles you might have missed from August 2022, including a discussion on fake medicines and what's needed to tackle their existence, the die down of SPAC deals and how device-activated drugs may unlock new therapeutic avenues.
You may also be interested in...
A selection of articles you might have missed from September 2022, including highlights from In Vivo's spotlight on rare diseases, their diagnosis and treatment.
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
The company has enrolled the first patient in the second human trial of its implantable metabolite monitoring system, which it expects could change the game for blood glucose measurement.